Cellectis S.A. (LON:0WA2)

London flag London · Delayed Price · Currency is GBP · Price in EUR
3.130
-0.245 (-7.26%)
At close: Feb 11, 2026
Market Cap197.81M +120.6%
Revenue (ttm)61.41M +129.0%
Net Income-26.30M
EPS-0.26
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,901
Average Volume2,765
Open3.373
Previous Close3.375
Day's Range3.130 - 3.340
52-Week Range1.124 - 4.840
Beta2.85
RSI38.81
Earnings DateMar 10, 2026

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric an... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 222
Stock Exchange London Stock Exchange
Ticker Symbol 0WA2
Full Company Profile

Financial Performance

In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.

Financial numbers in USD Financial Statements